Where are we heading to in pharmacological IBD therapy?

Pharmacological Research

Volumn 100, Issue , 2015, Pages 220-227

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Anti integrin; Anti TNF antibodies; antibodies; Inflammatory bowel disease; Pharmacological therapy; Therapy alghorithms

Indexed keywords

ADALIMUMAB; ANTHOCYANIN; C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; CHEMOKINE; CHEMOKINE RECEPTOR CCR9; CLAZAKIZUMAB; CYTOKINE; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; INTEGRIN; INTERLEUKIN 6 ANTIBODY; MATRIX METALLOPROTEINASE; MONGERSEN; OLOKIZUMAB; PF 04236921; PHOSPHATIDYLCHOLINE; PLACEBO; PROBIOTIC AGENT; RECOMBINANT INTERLEUKIN 10; RECOMBINANT PROTEIN; SIRUKUMAB; TOCILIZUMAB; TOFACITINIB; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; USTEKINUMAB; VEDOLIZUMAB; CELL ADHESION MOLECULE; INTERLEUKIN 10;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTISENSE THERAPY; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG TARGETING; FECAL MICROBIOTA TRANSPLANTATION; HUMAN; INFLAMMATORY BOWEL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN INDUCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; THERAPY WITH HELMINTHS; TREATMENT FAILURE; ULCERATIVE COLITIS; ANIMAL; INFLAMMATORY BOWEL DISEASES; METABOLISM;

ANIMALS; CELL ADHESION MOLECULES; HUMANS; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10;

EID: 84940912287     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2015.07.005     Document Type: Review

References (114)

1. S. Danese, and L. Peyrin-Biroulet IBD in 2013: enriching the therapeutic armamentarium for IBD Nat. Rev. Gastroenterol. Hepatol. 11 2014 84 86
2. H. Herfarth, and G. Rogler Inflammatory bowel disease Endoscopy 37 2005 42 47
3. G. Rogler The history and philosophy of inflammatory bowel disease Dig. Dis. 31 2013 270 277
4. M. Scharl, and G. Rogler Inflammatory bowel disease pathogenesis: what is new? Curr. Opin. Gastroenterol. 28 2012 301 309
5. G. Rogler Interaction between susceptibility and environment: examples from the digestive tract Dig. Dis. 29 2011 136 143
6. S.R. Vavricka, and G. Rogler Recent advances in the etiology and treatment of Crohn's disease Minerva Gastroenterol. Dietol. 56 2010 203 211
7. S. Foersch, M.J. Waldner, and M.F. Neurath Innate and adaptive immunity in inflammatory bowel diseases Dig. Dis. 31 2013 317 320
8. G. Rogler Recognition of commensal microbes: if innate responses are nod in balance Expert Rev. Clin. Immunol. 6 2010 205 210
9. P. Rutgeerts, G. van Assche, and S. Vermeire Optimizing anti-TNF treatment in inflammatory bowel disease Gastroenterology 126 2004 1593 1610
10. L. Yun, and S. Hanauer Selecting appropriate anti-TNF agents in inflammatory bowel disease Expert Rev. Gastroenterol. Hepatol. 3 2009 235 248
11. I. Ordas, D.R. Mould, B.G. Feagan, and et al. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms Clin. Pharmacol. Ther. 91 2012 635 646
12. S. Danese, J.F. Colombel, L. Peyrin-Biroulet, and et al. Review article: the role of anti-TNF in the management of ulcerative colitis - past, present and future Aliment. Pharmacol. Ther. 37 2013 855 866
13. L. Peyrin-Biroulet, G. Fiorino, A. Buisson, and et al. First-line therapy in adult Crohn's disease: who should receive anti-TNF agents? Nat. Rev. Gastroenterol. Hepatol. 10 2013 345 351
14. M.A. Samaan, P. Bagi, N. Vande Casteele, and et al. An update on anti-TNF agents in ulcerative colitis Gastroenterol. Clin. North Am. 43 2014 479 494
15. S.R. Targan, S.B. Hanauer, S.J. van Deventer, and et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's disease cA2 study group N. Engl. J. Med. 337 1997 1029 1035
16. P. Rutgeerts, G. D'Haens, S. Targan, and et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Gastroenterology 117 1999 761 769
17. F.J. Baert, G. D'Haens, M. Peeters, and et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis Gastroenterology 116 1999 22 28
18. W.J. Sandborn, G. van Assche, W. Reinisch, and et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 142 2012 257 265 e251-253
19. W. Reinisch, W.J. Sandborn, D.W. Hommes, and et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial Gut 60 2011 780 787
20. W.J. Sandborn, S.B. Hanauer, P. Rutgeerts, and et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial Gut 56 2007 1232 1239
21. J.F. Colombel, W.J. Sandborn, P. Rutgeerts, and et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Gastroenterology 132 2007 52 65
22. S.B. Hanauer, W.J. Sandborn, P. Rutgeerts, and et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial Gastroenterology 130 2006 323 333 quiz 591
23. W.J. Sandborn, S. Hanauer, E.V. Loftus Jr., and et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease Am. J. Gastroenterol. 99 2004 1984 1989
24. W.J. Sandborn, M.T. Abreu, G. D'Haens, and et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab Clin. Gastroenterol. Hepatol. 8 2010 688 695 e682
25. S. Schreiber, M. Khaliq-Kareemi, I.C. Lawrance, and et al. Maintenance therapy with certolizumab pegol for Crohn's disease N. Engl. J. Med. 357 2007 239 250
26. W.J. Sandborn, B.G. Feagan, S. Stoinov, and et al. Certolizumab pegol for the treatment of Crohn's disease N. Engl. J. Med. 357 2007 228 238
27. W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 96 109 e101
28. W.J. Sandborn, B.G. Feagan, C. Marano, and et al. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis Gastroenterology 146 2014 85 95 quiz e14-85
29. W.J. Sandborn, S.B. Hanauer, S. Katz, and et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial Gastroenterology 121 2001 1088 1094
30. Z. Xu, E. Bouman-Thio, C. Comisar, and et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-il-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study Br. J. Clin. Pharmacol. 72 2011 270 281
31. Y. Tanaka, and E. Martin Mola Il-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab Ann. Rheum. Dis. 73 2014 1595 1597
32. M.C. Genovese, R. Fleischmann, D. Furst, and et al. Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised phase iib study Ann. Rheum. Dis. 73 2014 1607 1615
33. D. Rossi, V. Modena, S. Sciascia, and et al. Rheumatoid arthritis: biological therapy other than anti-TNF Int. Immunopharmacol. 27 2015 185 188
34. J.F. Rossi, Z.Y. Lu, M. Jourdan, and et al. Interleukin-6 as a therapeutic target Clin. Cancer Res. 21 2015 1248 1257
35. L. Semerano, A. Thiolat, E. Minichiello, and et al. Targeting IL-6 for the treatment of rheumatoid arthritis: Phase II investigational drugs Expert Opin. Investig. Drugs 23 2014 979 999
36. P.T. Fan, and K.H. Leong The use of biological agents in the treatment of rheumatoid arthritis Ann. Acad. Med. Singapre 36 2007 128 134
37. M. Osman, D. Emery, and E. Yacyshyn Tocilizumab for treating Takayasu's arteritis and associated stroke: a case series and updated review of the literature J. Stroke Cerebrovasc. Dis. 24 2015 1291 1298
38. S. Rajalingham, and S. Das Antagonizing IL-6 in ankylosing spondylitis: a short review Inflammation Allergy Drug Targets 11 2012 262 265
39. S. Mori, T. Yoshitama, T. Hidaka, and et al. Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study) Ann. Rheum. Dis. 74 2015 627 630
40. M. Shimizu, Y. Hamaguchi, S. Ishikawa, and et al. Successful treatment with tocilizumab of a psoriasiform skin lesion induced by etanercept in a patient with juvenile idiopathic arthritis Mod. Rheumatol. 2014 1 2
41. M. Fernandes das Neves, S. Oliveira, M.C. Amaral, and et al. Treatment of systemic sclerosis with tocilizumab Rheumatology 54 2015 371 372
42. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, and et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease Gastroenterology 135 2008 1130 1141
43. P.J. Mannon, I.J. Fuss, L. Mayer, and et al. Anti-interleukin-12 antibody for active Crohn's disease N. Engl. J. Med. 351 2004 2069 2079
44. R. Panaccione, W.J. Sandborn, G.L. Gordon, and et al. Briakinumab for treatment of Crohn's disease: results of a randomized trial Inflamm. Bowel Dis. 21 2015 1329 1340
45. W. Hueber, B.E. Sands, S. Lewitzky, and et al. Secukinumab, a human anti-IL-17a monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial Gut 61 2012 1693 1700
46. W. Reinisch, J. Panes, S. Khurana, and et al. Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study Gut 64 2015 894 900
47. S. Danese, J. Rudzinski, W. Brandt, and et al. Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study Gut 64 2015 243 249
48. N.A. Hanania, M. Noonan, J. Corren, and et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies Thorax 70 2015 748 756
49. J. Corren, R.F. Lemanske, N.A. Hanania, and et al. Lebrikizumab treatment in adults with asthma N. Engl. J. Med. 365 2011 1088 1098
50. B.E. Sands, W.J. Sandborn, T.J. Creed, and et al. Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis Gastroenterology 143 2012 356 364.e1 e351
51. G. Van Assche, I. Dalle, M. Noman, and et al. A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis Am. J. Gastroenterol. 98 2003 369 376
52. G. Van Assche, W.J. Sandborn, B.G. Feagan, and et al. Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (cd25), for the treatment of moderately to severely active ulcerative colitis: A randomised, double blind, placebo controlled, dose ranging trial Gut 55 2006 1568 1574
53. S. Ghosh, E. Goldin, F.H. Gordon, and et al. Natalizumab for active Crohn's disease N. Engl. J. Med. 348 2003 24 32
54. W.J. Sandborn, J.F. Colombel, R. Enns, and et al. Natalizumab induction and maintenance therapy for Crohn's disease N. Engl. J. Med. 353 2005 1912 1925
55. G. Van Assche, M. Van Ranst, R. Sciot, and et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease N. Engl. J. Med. 353 2005 362 368
56. S.R. Targan, B.G. Feagan, R.N. Fedorak, and et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial Gastroenterology 132 2007 1672 1683
57. A. Sakuraba, M.L. Annunziata, R.D. Cohen, and et al. Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's disease Inflamm. Bowel Dis. 19 2013 2577 2583
58. A. Sakuraba, K. Keyashian, C. Correia, and et al. Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center Inflamm. Bowel Dis. 19 2013 621 626
59. B.E. Sands, B.G. Feagan, P. Rutgeerts, and et al. Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed Gastroenterology 147 2014 618 627 e613
60. S.J. Bickston, B.W. Behm, D.J. Tsoulis, and et al. Vedolizumab for induction and maintenance of remission in ulcerative colitis Cochrane Database Syst. Rev. 8 2014 CD007571
61. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, and et al. Vedolizumab as induction and maintenance therapy for Crohn's disease N. Engl. J. Med. 369 2013 711 721
62. B.G. Feagan, P. Rutgeerts, B.E. Sands, and et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis N. Engl. J. Med. 369 2013 699 710
63. H. Li, K. Kock, J.A. Wisler, and et al. Prediction of clinical pharmacokinetics of AMG 181, a human anti-alpha 4 beta 7 monoclonal antibody for treating inflammatory bowel diseases Pharmacol. Res. Perspect 3 2015 e00098
64. W.J. Pan, K. Kock, W.A. Rees, and et al. Clinical pharmacology of AMG 181, a gut-specific human anti-alpha4beta7 monoclonal antibody, for treating inflammatory bowel diseases Br. J. Clin. Pharmacol. 78 2014 1315 1333
65. W.J. Pan, H. Hsu, W.A. Rees, and et al. Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells Br. J. Pharmacol. 169 2013 51 68
66. S. Vermeire, S. O'Byrne, M. Keir, and et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial Lancet 384 2014 309 318
67. N. Pullen, E. Molloy, D. Carter, and et al. Pharmacological characterization of PF-00547659, an anti-human madcam monoclonal antibody Br. J. Pharmacol. 157 2009 281 293
68. L. Hassanieh, D. Rodriguez, J. Xu, and et al. Generation of a monoclonal antibody to a cryptic site common to both integrin beta1 as well as gelatinase MMP9 Hybrid. Hybridomics 22 2003 285 292
69. S. Keshav, T. Vanasek, Y. Niv, and et al. A randomized controlled trial of the efficacy and safety of CCX282-b, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease PloS one 8 2013 e60094
70. M. Yellin, I. Paliienko, A. Balanescu, and et al. A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis Arthritis Rheum. 64 2012 1730 1739
71. K.C. Bhol, D.E. Tracey, B.R. Lemos, and et al. Avx-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease Inflamm. Bowel Dis. 19 2013 2273 2281
72. R.N. Fedorak, A. Gangl, C.O. Elson, and et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The interleukin 10 inflammatory bowel disease cooperative study group Gastroenterology 119 2000 1473 1482
73. S. Schreiber, R.N. Fedorak, O.H. Nielsen, and et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's disease IL-10 cooperative study group Gastroenterology 119 2000 1461 1472
74. J.F. Colombel, P. Rutgeerts, H. Malchow, and et al. Interleukin 10 (tenovil) in the prevention of postoperative recurrence of Crohn's disease Gut 49 2001 42 46
75. B.E. Sands, S. Bank, C.A. Sninsky, and et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease Gastroenterology 117 1999 58 64
76. B.E. Sands, B.D. Winston, B. Salzberg, and et al. Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohn's disease Aliment. Pharmacol. Ther. 16 2002 399 406
77. K.R. Herrlinger, T. Witthoeft, A. Raedler, and et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease Am. J Gastroenterol. 101 2006 793 797
78. B.A. Karimi-Shah, and B.A. Chowdhury Forced vital capacity in idiopathic pulmonary fibrosis-FDA review of pirfenidone and nintedanib N. Engl. J. Med. 372 2015 1189 1191
79. T.E. King Jr., W.Z. Bradford, S. Castro-Bernardini, and et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis N. Engl. J. Med. 370 2014 2083 2092
80. P.W. Noble, C. Albera, W.Z. Bradford, and et al. Pirfenidone in patients with idiopathic pulmonary fibrosis two randomised trials Lancet 377 2011 1760 1769
81. G. Canesin, E.P. Cuevas, V. Santos, and et al. Lysyl oxidase-like 2 (LOXL2) and e47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization Oncogene 34 2015 951 964
82. D.X. Hou, M. Fujii, N. Terahara, and et al. Molecular mechanisms behind the chemopreventive effects of anthocyanidins J. Biomed. Biotechnol. 2004 2004 321 325
83. N.C. Veitch, and R.J. Grayer Flavonoids and their glycosides, including anthocyanins Nat. Prod. Rep. 25 2008 555 611
84. T.K. McGhie, and M.C. Walton The bioavailability and absorption of anthocyanins: towards a better understanding Mol. Nutr. Food Res. 51 2007 702 713
85. S. Zafra-Stone, T. Yasmin, M. Bagchi, and et al. Berry anthocyanins as novel antioxidants in human health and disease prevention Mol. Nutr. Food Res. 51 2007 675 683
86. S. Roth, M.R. Spalinger, I. Muller, and et al. Bilberry-derived anthocyanins prevent IFN-gamma-induced pro-inflammatory signalling and cytokine secretion in human THP-1 monocytic cells Digestion 90 2014 179 189
87. H. Piberger, A. Oehme, C. Hofmann, and et al. Bilberries and their anthocyanins ameliorate experimental colitis Mol. Nutr. Food Res. 55 2011 1724 1729
88. L. Biedermann, J. Mwinyi, M. Scharl, and et al. Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis - an open pilot study J. Crohn's Colitis 7 2013 271 279
89. C. Jobin, C.A. Bradham, M.P. Russo, and et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity J. Immunol. 163 1999 3474 3483
90. L. Camacho-Barquero, I. Villegas, J.M. Sanchez-Calvo, and et al. Curcumin, a curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis Int. Immunopharmacol. 7 2007 333 342
91. R.A. Taylor, and M.C. Leonard Curcumin for inflammatory bowel disease: a review of human studies Altern. Med. Rev. 16 2011 152 156
92. C. Lahiff, and A.C. Moss Curcumin for clinical and endoscopic remission in ulcerative colitis Inflamm. Bowel Dis. 17 2011 E66
93. A.C. Moss Curcumin for maintenance therapy in ulcerative colitis Clin. Gastroenterol. Hepatol. 5 2007 642
94. H. Hanai, T. Iida, K. Takeuchi, and et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial Clin. Gastroenterol. Hepatol. 4 2006 1502 1506
95. A. Lang, N. Salomon, J.C. Wu, and et al. Curcumin in combination with mesalamine induces remission in patients with mild-to-moderate ulcerative colitis in a randomized controlled trial Clin. Gastroenterol. Hepatol. 13 2015 1444 1449
96. J. Langhorst, I. Varnhagen, S.B. Schneider, and et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis-a double-blind, double-dummy study Aliment. Pharmacol. Ther. 38 2013 490 500
97. S. Schreiber, S. Nikolaus, H. Malchow, and et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease Gastroenterology 120 2001 1339 1346
98. B.R. Yacyshyn, W.Y. Chey, J. Goff, and et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease Gut 51 2002 30 36
99. P.B. Miner Jr., R.S. Geary, J. Matson, and et al. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis Aliment. Pharmacol. Ther. 23 2006 1427 1434
100. G. Monteleone, M.F. Neurath, S. Ardizzone, and et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease N. Engl. J. Med. 372 2015 1104 1113
101. W.J. Sandborn, S. Ghosh, J. Panes, and et al. Tofacitinib, an oral janus kinase inhibitor, in active ulcerative colitis N. Engl. J. Med. 367 2012 616 624
102. W.J. Sandborn, S. Ghosh, J. Panes, and et al. A phase 2 study of tofacitinib, an oral janus kinase inhibitor, in patients with Crohn's disease Clin. Gastroenterol. Hepatol. 12 2014 1485 1493
103. T. Sugiura, S. Kageyama, A. Andou, and et al. Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice J. Crohn's Colitis 7 2013 e533 542
104. G. D'Haens, W.J. Sandborn, J.F. Colombel, and et al. A phase II study of laquinimod in Crohn's disease Gut 2014
105. W. Stremmel, A. Braun, A. Hanemann, and et al. Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study J. Clin. Gastroenterol. 44 2010 e110 107
106. W. Stremmel, R. Ehehalt, F. Autschbach, and et al. Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial Ann. Intern. Med. 147 2007 603 610
107. W. Stremmel, R. Ehehalt, S. Staffer, and et al. Mucosal protection by phosphatidylcholine Dig. Dis. 30 Suppl 3 2012 85 91
108. W. Stremmel, U. Merle, A. Zahn, and et al. Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis Gut 54 2005 966 971
109. E. van Nood, A. Vrieze, M. Nieuwdorp, and et al. Duodenal infusion of donor feces for recurrent clostridium difficile N. Engl. J. Med. 368 2013 407 415
110. N.G. Rossen, S. Fuentes, M.J. van der Spek, and et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis Gastroenterology 149 2015 110 118
111. P. Moayyedi, M.G. Surette, P.T. Kim, and et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial Gastroenterology 149 2015 102 109
112. R.W. Summers, D.E. Elliott, K. Qadir, and et al. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease Am. J. Gastroenterol. 98 2003 2034 2041
113. R.W. Summers, D.E. Elliott, and J.F. Urban et al Jr. Trichuris suis therapy in Crohn's disease Gut 54 2005 87 90
114. R.W. Summers, D.E. Elliott, J.F. Urban Jr., and et al. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial Gastroenterology 128 2005 825 832